DECIBEL THERAPEUTICS INC's ticker is DBTX and the CUSIP is 24343R106. A total of 44 filers reported holding DECIBEL THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,472,951 | +27.5% | 642,325 | 0.0% | 0.00% | – |
| Q1 2023 | $1,939,821 | +50.8% | 642,325 | +2.4% | 0.00% | – |
| Q4 2022 | $1,285,973 | -40.3% | 627,304 | +0.7% | 0.00% | – |
| Q3 2022 | $2,155,000 | -17.8% | 622,937 | 0.0% | 0.00% | – |
| Q2 2022 | $2,622,000 | +38.5% | 622,937 | 0.0% | 0.00% | – |
| Q1 2022 | $1,893,000 | -34.9% | 622,937 | -0.3% | 0.00% | – |
| Q4 2021 | $2,906,000 | -39.7% | 624,797 | -0.1% | 0.00% | – |
| Q3 2021 | $4,820,000 | +50.8% | 625,215 | +68.2% | 0.00% | – |
| Q2 2021 | $3,197,000 | +53.6% | 371,774 | +102.9% | 0.00% | – |
| Q1 2021 | $2,082,000 | – | 183,259 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,139,685 | $9,545,000 | 2.59% |
| Samsara BioCapital, LLC | 826,422 | $2,512,000 | 0.63% |
| Orbimed Advisors | 4,945,192 | $15,033,000 | 0.24% |
| Alphabet Inc. | 1,636,258 | $4,974,000 | 0.16% |
| HARVARD MANAGEMENT CO INC | 328,798 | $1,000,000 | 0.10% |
| Casdin Capital, LLC | 330,000 | $1,003,000 | 0.04% |
| Bronte Capital Management Pty Ltd. | 163,224 | $496,000 | 0.04% |
| MYDA Advisors LLC | 20,000 | $61,000 | 0.02% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 263,600 | $801,000 | 0.02% |
| ATLAS CAPITAL ADVISORS LLC | 41,025 | $124,716,000 | 0.02% |